Pep IQ
← Pep IQ
Substantial preclinical foundation within the Khavinson research program. Pinealon (Glu-Asp-Arg, EDR) is a synthetic tripeptide developed by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology. Mechanism: claimed direct peptide-DNA interaction at gene promoter regions, modulating gene expression in neurons. Published mouse work — Khavinson et al. 2021 (Pharmaceuticals, MDPI) — showed neuroprotective effects in transgenic Alzheimer's mouse models. Khavinson et al. 2017 — neuroprotective effect of EDR peptide in Huntington's disease mouse model. Arutjunyan et al. 2012 — Pinealon protected rat offspring from prenatal hyperhomocysteinemia and cognitive deficits. Mendzheritskii 2014 — effects on navigation learning and caspase-3 systems in rats of different ages. Rhesus macaque cognitive rehabilitation study (Georgievna et al. 2019, Moscow University Anthropology Bulletin).
Community protocols converge on 1–2 mg SubQ daily for 10–20 day courses, repeated 2–3 times per year. Some users go oral at higher doses (10–20 mg/day) but oral bioavailability of the tripeptide is uncertain. Cycle structure mirrors the Khavinson clinical framework — short courses, multiple times per year, rather than continuous use. Often stacked with Epitalon (parallel Khavinson tetrapeptide for telomerase pathway) in geroprotection protocols.
The clinical evidence base is essentially the Khavinson Russian research corpus — extensive but published primarily in Russian journals and not independently replicated by Western institutions. Recess Rx Clinical Reference compiles the Russian protocols. Some published rat and mouse studies in Western journals (Pharmaceuticals 2021, J Neurol Neurosci 2017). No completed large-scale human clinical trials outside Russia. The 'peptide-DNA direct interaction' mechanism Khavinson proposes has not been independently confirmed by Western molecular biology groups — peptides this small entering nuclei and binding DNA at promoters is theoretically possible but would be unusual and remains controversial.
Not approved by any major Western regulatory agency (FDA, EMA, MHRA). Available in Russia and via research peptide vendors elsewhere. The Khavinson framework as a whole occupies an unusual position — decades of Russian research with a coherent theoretical model, but very limited Western replication or independent validation.
Pinealon sits firmly in the Khavinson bioregulator framework alongside Epitalon and Thymalin — extensive Russian research base, plausible mechanism (peptides crossing membranes via PEPT2 transport is established), but the specific 'direct peptide-DNA interaction at gene promoters' claim has not been independently verified by Western groups, and no large-scale Western human trials exist. Standard protocol: 1–2 mg SubQ daily for 10–20 days, 2–3 cycles per year. Pep IQ flags this honestly: the mechanism evidence is real but unverified outside Russia, and members considering Pinealon are accepting the Khavinson framework on the strength of his program rather than independent Western validation. Among the cleaner short-cycle compounds if you accept that framework.
Pinealon is part of the same Khavinson bioregulator research programme that produced Epitalon. Where Epitalon was derived from pineal gland extract, Pinealon (EDR — Glu-Asp-Arg) was isolated from Cortexin — a clinically approved polypeptide complex derived from the cerebral cortex of calves and pigs, used medically in Russia for neurological conditions.
The logic behind ultra-short peptides like Pinealon is one of the more interesting ideas in this space: small peptides may be able to enter cells and interact directly with DNA regulatory regions, effectively acting as epigenetic switches for gene expression. Pinealon's three amino acid structure gives it extremely high stability and tissue penetration compared to larger peptides — and its arginine content is associated with neuroprotective properties in several peptide classes.
What makes Pinealon distinct from DSIP or Epitalon is its framing. It is not positioned as producing acute effects — no immediate sleep improvement, no burst of energy. It is proposed as long-term neuroprotective infrastructure: upregulating the antioxidant defences neurons need to resist the oxidative damage that accumulates over decades of life. Benefits, if real, would manifest over years rather than weeks.
Important context: Like Epitalon, most Pinealon research originates from Khavinson's group in Russia. It shares all the same single-source caveats. Independent Western replication of Pinealon specifically is very limited. The 2025 systematic review on related Khavinson peptides noted that "information regarding critical issues about this peptide's safety is missing." This is an honest summary of where the evidence stands.
Pinealon's proposed mechanism is unusual even within peptide science. Its tiny three amino acid structure — with a molecular weight of roughly 390 Daltons — means it is small enough to enter cells and potentially penetrate into the cell nucleus itself. Research suggests it can interact with the major groove of DNA, specifically affecting guanine base atoms, and may bind to histone proteins to modulate chromatin structure and gene expression.
The direct DNA interaction mechanism is scientifically unusual and requires context. Peptides interacting directly with DNA is not unprecedented, but a three amino acid sequence producing specific, targeted gene expression changes is a mechanistic claim that needs substantial independent replication before it can be treated as established. The molecular dynamics studies support the plausibility of DNA binding, but the downstream functional consequences in humans remain incompletely characterised.